학술논문

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Document Type
Article
Source
In The Lancet 5-11 August 2017 390(10094):555-566
Subject
Primary Research
Articles
Language
ISSN
0140-6736